Sepsis remains one of the world’s most urgent and life-threatening medical emergencies. It develops when the body’s response to an infection becomes overwhelming, potentially leading to widespread inflammation, organ dysfunction, septic shock, and, in severe cases, death. Every year, millions of people worldwide are affected by sepsis, making early recognition and timely intervention critical to improving patient outcomes.
At Delphine Diagnostics, our mission is clear: to help save lives by advancing technologies that support earlier detection and faster clinical decision-making in sepsis care.
Understanding the Urgency of Sepsis
Sepsis often begins with a bacterial, viral, or fungal infection that can rapidly escalate if not identified and treated promptly. As the condition progresses, patients may develop septic shock, a serious medical emergency that can significantly impair the function of vital organs, including the heart, lungs, liver, and kidneys.
Because the early signs of sepsis can be subtle and resemble other illnesses, delayed diagnosis remains one of the biggest challenges faced by healthcare professionals. Detecting sepsis before it progresses to septic shock can make a significant difference in patient outcomes.
A Personal Story That Reinforces Our Purpose
The importance of early sepsis detection is deeply personal for many families.
One such experience involved the tragic loss of a loved one whose infection originated in the lungs before rapidly progressing to sepsis and ultimately cardiac failure. Like countless families around the world, this experience highlights how quickly sepsis can develop and why greater awareness, earlier diagnosis, and timely intervention are so important.
Stories like these reinforce the urgent need for continued innovation in diagnostic technologies that support clinicians when every minute counts.
Driving Innovation for Earlier Detection
At Delphine Diagnostics, we are developing innovative technologies designed to assist healthcare professionals in identifying patients who may be at risk of sepsis earlier in the clinical journey.
Our research and development efforts are focused on two complementary solutions:
AI-Powered Clinical Decision Support
Delphine’s Clinical Decision Support Assistant (CDSA) leverages Artificial Intelligence (AI) and Machine Learning (ML) to analyze clinical data and provide healthcare professionals with actionable insights that may support earlier recognition of patients at risk of developing sepsis.
By helping transform complex patient information into meaningful clinical insights, AI has the potential to support faster and more informed decision-making.
Advanced Molecular Diagnostic Testing
In parallel, Delphine Diagnostics is developing a molecular diagnostic assay designed to help identify the underlying pathogen responsible for infection and provide clinically relevant information that may assist healthcare professionals in selecting appropriate treatment strategies.
Together, these technologies are intended to complement existing clinical workflows and support more timely diagnosis and intervention.
Note: These technologies are currently under development and are intended to undergo applicable regulatory review before becoming available for clinical use.
A Vision for Better Patient Outcomes
At Delphine Diagnostics, we believe innovation should serve a greater purpose—improving lives. By combining advanced molecular diagnostics, artificial intelligence, and scientific research, we are working toward solutions that empower healthcare professionals with faster, more reliable diagnostic insights.
While no single technology can eliminate the challenges of sepsis, continued innovation has the potential to improve clinical decision-making, support earlier intervention, and ultimately contribute to better patient outcomes.
Our Commitment
Sepsis demands urgency, innovation, and collaboration.
Delphine Diagnostics remains committed to developing next-generation diagnostic solutions that support healthcare providers in delivering timely, informed, and effective patient care.
Every advancement brings us one step closer to a future where sepsis is recognized earlier, treated more effectively, and where more lives can be saved through innovation.